(Total Views: 313)
Posted On: 07/10/2020 6:47:31 AM
Post# of 72
From Christopher Reinhard
Hi XXXXXXX
"Many thanks for your email. I hope that you and your family are likewise staying safe and healthy. Our business plan remains unchanged from my previous emails. With new access to capital, additional skilled resources and infrastructure support, as a result of our recently completed transaction with Nostrum, we are in the process of brining our SEC filings up to date, up- listing of our stock, the manufacturing of the Ad5FGF-4 product candidate for planned clinical study, and preparing to start our FDA-cleared Phase 3 clinical study. As you may know, me and a small team here in San Diego over the past 20 years have advanced Ad5FGF-4 from a bench lab at the University of California San Diego, and now into Phase 3 clinical studies, and we look forward to completing the planned Phase 3 clinical study intended to commercially market and sell Ad5FGF-4, first in the U.S., and then worldwide."
Hi XXXXXXX
"Many thanks for your email. I hope that you and your family are likewise staying safe and healthy. Our business plan remains unchanged from my previous emails. With new access to capital, additional skilled resources and infrastructure support, as a result of our recently completed transaction with Nostrum, we are in the process of brining our SEC filings up to date, up- listing of our stock, the manufacturing of the Ad5FGF-4 product candidate for planned clinical study, and preparing to start our FDA-cleared Phase 3 clinical study. As you may know, me and a small team here in San Diego over the past 20 years have advanced Ad5FGF-4 from a bench lab at the University of California San Diego, and now into Phase 3 clinical studies, and we look forward to completing the planned Phase 3 clinical study intended to commercially market and sell Ad5FGF-4, first in the U.S., and then worldwide."
(1)
(0)Scroll down for more posts ▼
